| Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer F Rojo, J Garcia-Parra, S Zazo, I Tusquets, J Ferrer-Lozano, S Menendez, ... Annals of oncology 23 (5), 1156-1164, 2012 | 211 | 2012 |
| Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis C Chamizo, J Moreno, J Alvar Veterinary immunology and immunopathology 103 (1-2), 67-75, 2005 | 160 | 2005 |
| The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy J Moreno, J Nieto, C Chamizo, F González, F Blanco, DC Barker, J Alvar Veterinary immunology and immunopathology 71 (3-4), 181-195, 1999 | 151 | 1999 |
| Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer J Madoz-Gúrpide, S Zazo, C Chamizo, V Casado, C Caramés, E Gavín, ... Journal of translational medicine 13, 1-13, 2015 | 88 | 2015 |
| Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer MA Sabbaghi, G Gil-Gómez, C Guardia, S Servitja, O Arpí, ... Clinical Cancer Research 23 (22), 7006-7019, 2017 | 83 | 2017 |
| HIV-Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy J Moreno, C Cañavate, C Chamizo, F Laguna, J Alvar Transactions of the Royal Society of Tropical Medicine and Hygiene 94 (3 …, 2000 | 57 | 2000 |
| Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines S Zazo, P González-Alonso, E Martín-Aparicio, C Chamizo, I Cristóbal, ... American journal of cancer research 6 (11), 2661, 2016 | 54 | 2016 |
| Semi-quantitative analysis of multiple cytokines in canine peripheral blood mononuclear cells by a single tube RT-PCR C Chamizo, JM Rubio, J Moreno, J Alvar Veterinary immunology and immunopathology 83 (3-4), 191-202, 2001 | 54 | 2001 |
| Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer A Dalmases, I González, S Menendez, O Arpí, JM Corominas, S Servitja, ... Oncotarget 5 (1), 196, 2014 | 48 | 2014 |
| Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy L del Puerto-Nevado, F Rojo, S Zazo, C Carames, G Rubio, R Vega, ... British journal of cancer 110 (11), 2700-2707, 2014 | 36 | 2014 |
| Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer J García-Parra, A Dalmases, B Morancho, O Arpí, S Menendez, ... European Journal of Cancer 50 (15), 2725-2734, 2014 | 32 | 2014 |
| Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer S Zazo, P Gonzalez-Alonso, E Martin-Aparicio, C Chamizo, M Luque, ... Molecular Cancer Therapeutics 19 (8), 1696-1707, 2020 | 27 | 2020 |
| Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer C Chamizo, S Zazo, M Dómine, I Cristóbal, J García-Foncillas, F Rojo, ... BMC pulmonary medicine 15, 1-7, 2015 | 22 | 2015 |
| The hippo pathway transducers YAP1/TEAD induce acquired resistance to trastuzumab in HER2-positive breast cancer P González-Alonso, S Zazo, E Martín-Aparicio, M Luque, C Chamizo, ... Cancers 12 (5), 1108, 2020 | 16 | 2020 |
| Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway F Rojo, L Domingo, M Sala, S Zazo, C Chamizo, S Menendez, O Arpi, ... Cancer Epidemiology, Biomarkers & Prevention 23 (2), 288-299, 2014 | 15 | 2014 |
| c-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer R Rincón, S Zazo, C Chamizo, R Manso, P González-Alonso, ... Molecular Cancer Therapeutics 15 (11), 2780-2790, 2016 | 13 | 2016 |
| Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution? M Boiza-Sánchez, R Manso, O Balagué, C Chamizo, E Askari, ... Plos one 15 (11), e0241634, 2020 | 7 | 2020 |
| Determination of true ERBB2 gene amplification in breast cancer by quantitative PCR using a reference and a novel control gene C Chamizo, F Rojo, J Madoz-Gurpide Applied Immunohistochemistry & Molecular Morphology 24 (3), 179-187, 2016 | 7 | 2016 |
| Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T‐cell lymphoma. R Manso, N Martínez‐Magunacelaya, C Chamizo, F Rojo, MÁ Piris, ... British Journal of Haematology 182 (4), 2018 | 6 | 2018 |
| Recent insights into the development of preclinical trastuzumab-resistant HER2+ breast cancer models P Gonzalez-Alonso, I Cristobal, S Zazo, E Martin-Aparicio, C Chamizo, ... Current Medicinal Chemistry 25 (17), 1976-1998, 2018 | 6 | 2018 |
